HIGHLIGHTS
- who: Top from the Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA have published the research: Evaluating clinical and prognostic implications of Glypican-3 in, in the Journal: (JOURNAL)
- what: In patients with HCC histopathogical differentiation is an important indicator of prognosis; however because determination of HCC differentiation is difficult the recently described immunohistochemical (IHC) marker glypican3 (GPC3) might assist in HCC prognostication.The goal of the study was to investigate GPC3's IHC staining pattern and define the relationship between its expression and patients' clinicopathologic features . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.